Genomic Medicine Sweden

Reference number 2018-04499
Coordinator Region Skåne - Skånes Universitetssjukhus
Funding from Vinnova SEK 38 773 089
Project duration November 2018 - June 2020
Status Ongoing

Purpose and goal

The Genomic Medicine Sweden (GMS) initiative aims to strengthen precision medicine across the country. This will be accomplished through the implementation of large-scale sequencing techniques in Swedish healthcare, resulting in improved healthcare, strengthened Swedish research in the area, and a foundation for innovation and collaboration with industry. With a patient-centered view, we will focus on rare diseases, cancer, pharmacogenetics and infectious diseases. In parallel, efforts will be initiated for common complex diseases for the next phase of GMS.

Expected results and effects

GMS will offer Swedish patients cutting edge diagnostics with possibilities of individually tailored therapy alternatives, where previously none was available. GMS will also offer a unique research resource for Sweden for identifying disease-causing events that could pave the way for new drug development, new treatment options, and enhance collaboration with industry. In summary, GMS provides Sweden with a unique opportunity to take an international forefront position in the field of precision medicine.

Planned approach and implementation

GMS will be implemented as a broad collaborative project between different societal stakeholders including health care providers, universities with medical faculties, Science for Life Laboratory, industry and patient organizations. In order to deliver top tier diagnostics and research, enabling individually adapted therapies and follow-up strategies, regional genomic medicine centers are being formed together with a national informatics infrastructure for data processing, interpretation and storage.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.